119 related articles for article (PubMed ID: 15380337)
1. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders.
Bock O; Tessema M; Serinsöz E; von Wasielewski R; Büsche G; Kreipe H
Leuk Res; 2004 Nov; 28(11):1145-51. PubMed ID: 15380337
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
4. Transcription factor Fli-1 expression by bone marrow cells in chronic myeloproliferative disorders is independent of an underlying JAK2 (V617F) mutation.
Bock O; Hussein K; Neusch M; Schlué J; Wiese B; Kreipe H
Eur J Haematol; 2006 Dec; 77(6):463-70. PubMed ID: 16930139
[TBL] [Abstract][Full Text] [Related]
5. Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis.
Bock O; Neusch M; Büsche G; Mengel M; Kreipe H
Eur J Haematol; 2004 Apr; 72(4):239-44. PubMed ID: 15089760
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia.
Serinsöz E; Neusch M; Büsche G; Wasielewski R; Kreipe H; Bock O
Br J Haematol; 2004 Aug; 126(3):313-9. PubMed ID: 15257703
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
Rudzki Z; Papla B; Stachura J
Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
[TBL] [Abstract][Full Text] [Related]
8. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
10. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
Kreipe HH
Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
[TBL] [Abstract][Full Text] [Related]
11. [The chronic Philadelphia chromosome-negative myeloproliferative syndrome I. Pathogenesis and pathophysiology].
Hasselbalch HC; Mourits-Andersen HT; Jensen BA; Jensen MK; Nielsen OJ
Ugeskr Laeger; 2001 Apr; 163(18):2471-3. PubMed ID: 11379259
[TBL] [Abstract][Full Text] [Related]
12. Single chromosomal abnormalities in Philadelphia-negative chronic myeloproliferative disorders.
Panani AD
In Vivo; 2007; 21(5):867-70. PubMed ID: 18019426
[TBL] [Abstract][Full Text] [Related]
13. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
14. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.
Johansson P; Kutti J; Andréasson B; Safai-Kutti S; Vilén L; Wedel H; Ridell B
J Intern Med; 2004 Aug; 256(2):161-5. PubMed ID: 15257729
[TBL] [Abstract][Full Text] [Related]
15. VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders.
Gianelli U; Vener C; Raviele PR; Savi F; Somalvico F; Calori R; Iurlo A; Radaelli F; Fermo E; Bucciarelli P; Bori S; Coggi G; Deliliers GL
Am J Clin Pathol; 2007 Dec; 128(6):966-73. PubMed ID: 18024322
[TBL] [Abstract][Full Text] [Related]
16. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
[TBL] [Abstract][Full Text] [Related]
17. AML transformation in 56 patients with Ph- MPD in two well defined populations.
Abdulkarim K; Girodon F; Johansson P; Maynadié M; Kutti J; Carli PM; Bovet E; Andréasson B
Eur J Haematol; 2009 Feb; 82(2):106-11. PubMed ID: 19134023
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders.
Passamonti F; Pietra D; Malabarba L; Rumi E; Della Porta MG; Malcovati L; Bonfichi M; Pascutto C; Lazzarino M; Cazzola M
Br J Haematol; 2004 Sep; 126(5):650-6. PubMed ID: 15327515
[TBL] [Abstract][Full Text] [Related]
19. Expression of insulin-like growth factor system genes in liver and brain tissue during embryonic and post-hatch development of the turkey.
Richards MP; Poch SM; McMurtry JP
Comp Biochem Physiol A Mol Integr Physiol; 2005 May; 141(1):76-86. PubMed ID: 15905111
[TBL] [Abstract][Full Text] [Related]
20. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
